Stockscreener 앱 받기
7.59
0.26%
0.02
시간 외 거래:
7.62
0.03
+0.40%
전일 마감가:
$7.57
열려 있는:
$7.635
하루 거래량:
4.92M
Relative Volume:
1.00
시가총액:
$1.60B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-42.17
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
-1.43%
1개월 성능:
+7.20%
6개월 성능:
-26.81%
1년 성능:
+0.80%
1일 변동 폭
$7.435
$7.915
1주일 범위
$7.23
$7.915
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.59 | 1.59B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
120.98 | 52.29B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.61 | 45.27B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 42.39B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.13 | 34.18B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
500.30 | 21.27B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
FDA extends Orladeyo approval to children as young as 2 - Angioedema News
BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
The Technical Signals Behind (BCRX) That Institutions Follow - news.stocktradersdaily.com
Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn
FDA approves BioCryst’s oral pellet version of rare disease drug for children - WKZO
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst wins FDA approval for Orladeyo oral pellets - MSN
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval - Investing.com
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
BioCryst’s Orladeyo wins expanded FDA approval - The Pharma Letter
BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug - Benzinga
BioCryst Announces Board Chair Transition Plan - TipRanks
FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema - Contemporary Pediatrics
Sector Update: Health Care Stocks Edge Higher Premarket Friday - marketscreener.com
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits
BioCryst stock rises after FDA approves ORLADEYO oral pellets for children - Investing.com Canada
FDA Approves BioCryst's (BCRX) Oral Pellet Formulation of Orlade - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children - Investing.com
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha
FDA Gives Green Light to BioCryst's (BCRX) ORLADEYO for Pediatri - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals Announces FDA Approval of ORLADEYO Oral Pellets as First Targeted Prophylactic Therapy for Pediatric Patients with HAE Aged 2 and Older - Quiver Quantitative
FDA expands approval of BioCryst's rare disease drug for use in young children - marketscreener.com
BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan
Nebula Research & Development LLC Invests $2.57 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com India
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight - The Globe and Mail
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - moha.gov.vn
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Jump Financial LLC - MarketBeat
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Would You Still Hold BioCryst Pharmaceuticals Stock If It Fell 30%? - Trefis
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership - MarketBeat
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why BioCryst Pharmaceuticals Inc. stock is seen as undervalued2025 Short Interest & Verified Short-Term Trading Plans - Newser
Is BioCryst Pharmaceuticals Inc. stock a good choice for value investorsVolume Spike & Reliable Price Action Trade Plans - Newser
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock - MarketBeat
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock - MarketBeat
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
BioCryst Pharma (BCRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Panagora Asset Management Inc. Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.98%
자본화:
|
볼륨(24시간):